Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuronal Chloride Cotransporter Modulators, Epilepsy & Neuropathic Pain Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KCC2/SLC12A5 drug discovery. Given the 12-transmembrane domain complexity of this potassium-chloride cotransporter, cell-based functional assays are essential for mechanism validation:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLC12A5 (KCC2) Full-Length Membrane Protein / Extracellular Domain Peptides Sequence Verified. HEK293 Expressed. High Purity (>95%), Endotoxin <1 EU/µg. Note: Complex 12-TM topology requires lipid bilayer context for native conformation. |
View KCC2 Products |
| Gene Delivery | SLC12A5 Lentivirus Premade Particles High-titer (≥1×10^8 TU/mL), Puromycin selectable. For stable cell line generation in ion flux assays, preserving native conformation and glycosylation. |
View KCC2 Products |
| Benchmark Ab | Anti-SLC12A5 (KCC2) Recombinant Monoclonal Antibody Sequence-verified clone, suitable for Surface Expression ELISA, Western Blot, and Immunocytochemistry. |
View KCC2 Products |
| Validator | SLC12A5 siRNA Set (Validated Trio) Gene-specific knockdown sequences for specificity controls in transport assays. Endotoxin Controlled. |
View KCC2 Products |
| Selectivity Panel | SLC12A4 (KCC1) Lentivirus & Protein Closest paralog (88% sequence homology), essential for counter-screening allosteric modulators. |
View SLC12A4 Products |
| Pathway Control | SLC12A2 (NKCC1) Reagents Opposite functional cotransporter (Na-K-Cl) for balance-of-excitation studies. |
View SLC12A2 Products |
| Related Target | GABA-A Receptor Downstream synergistic signaling partner for inhibitory transmission. |
View GABRA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| 12-TM Conformation Integrity | Lentivirus-Mediated Stable Expression (Native membrane context, correct glycosylation on Loop 5) |
| KCC1 vs KCC2 Selectivity (88% Homology) | Human/Mouse/Rat Ortholog Panels available with sequence-verified extracellular loop distinctions |
| Functional Ion Transport Readout | High-expression lentiviral titers (≥10^8 TU/mL) enabling robust Rb+/Tl+ flux assays in stable lines |
| Cross-Species Translation (CNS) | Cyno/Mouse/Rat SLC12A5 ORF available with endotoxin <1EU/μg for translational pharmacology |
| Subfamily Counter Screening (vs NKCC1) | Sequence-verified Ortholog and Paralog viral vectors for strict selectivity profiling |
| Target Validation in Native Cells | Validated siRNA included for precise endogenous target knockdown |
Live KCC2/SLC12A5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLC12A5-targeted therapeutics is transitioning from genetic validation to pharmacological modulation. While traditional antiepileptic drugs target ion channels directly, the next wave focuses on chloride homeostasis modulation via KCC2 allosteric activators. As first-generation small molecules enter Phase I for refractory epilepsy and neuropathic pain, the critical R&D bottleneck lies in distinguishing functional transporter activation from surface expression upregulation—a distinction requiring sophisticated cell-based assays. Major players include Biogen, Ovid Therapeutics, and academic consortia, with modalities spanning small molecule PAMs, gene therapy (AAV-KCC2), and peptide therapeutics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Allosteric Activators (Small Molecule) | Biogen, Ovid Therapeutics, Academic Consortia | Refractory Epilepsy, Dravet Syndrome, Neuropathic Pain | Rb+ Flux Assay (Need high-expression stable cell lines via Lentivirus) |
| Gene Therapy (AAV-KCC2) | Neuro-focused Gene Therapy Biotechs | Neuropathic Pain, Spinal Cord Injury, ASD | Overexpression Validation (Need full-length ORF Lentivirus and specific Reference Abs) |
| SLC12 Family Inhibitors | Preclinical Discovery | Stroke, Ischemia | Selectivity Panel (Need SLC12A4/KCC1 counter-screen) |
| Peptide Therapeutics | Early-stage biotechs | Neuroprotection | Functional screening (Need stable cell lines via Lentivirus) |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors
-
Subtype Selectivity (KCC1 vs KCC2): SLC12A4 (KCC1) shares 88% amino acid homology with SLC12A5, but key residues in TM7-8 differ (e.g., KCC2 Gln622 vs KCC1 Met610). Counter-screening against KCC1 is essential to avoid off-target effects.
-
Functional Activation vs. Expression Upregulation: Next-generation R&D must distinguish between compounds that directly enhance transport Vmax and those that stabilize surface expression by inhibiting internalization. This requires paired assays: Surface ELISA for expression and Flux Assay for activity.
-
KCC2a vs KCC2b Isoform Selectivity: Neuron-specific KCC2b (containing cassette exon 25) versus ubiquitously expressed KCC2a will be key for differentiating epilepsy vs. peripheral pain indications.
-
BBB Penetration: Small molecule drugs must have excellent blood-brain barrier penetration and appropriate free brain concentration (Kp,uu).
Recommended Screening Assays
- Thallium (Tl+) Flux Assay: Gold standard for high-throughput screening of KCC2 activity, using fluorescent dyes to detect ion channel opening.
- Automated Patch-Clamp (APC): Secondary confirmation for precise electrophysiological characterization.
- Western Blot / Flow Cytometry: Using specific antibodies to assess total vs. membrane-localized KCC2 (Surface Biotinylation assay).
TarMart Solution
- Lentivirus Products: High-titer premade particles for human and mouse KCC2 and NKCC1, enabling rapid construction of stable HEK293/CHO cell lines for Tl+ flux screening and selectivity profiling.
- Benchmark Antibodies: Sequence-verified high-affinity KCC2 antibodies for internalization assays and membrane expression quantification (FACS/WB), eliminating false positives from poor polyclonal antibodies.